

What is claimed is:

1. A method of identifying a psychoactive compound, comprising contacting a cell with a test compound and determining a level of expression of a psychoactive-associated gene in the cell, wherein an increase or decrease of said level compared to a normal control level of said gene indicates that the test compound is a psychoactive compound
2. The method of claim 1, wherein said psychoactive-associated gene is selected from the group consisting of PTX3, ILK, ENTPD6, GPCR CG50207, SFRS7, CBRC7TM_424 GPCR, APAF-1, ERMAP, CGFLC_31120, LYPLA1, LDHA, SCG3 and CG187132.
3. The method of claim 1, wherein said method further comprises determining said level of expression of a plurality of psychoactive -associated genes.
4. The method of claim 1, wherein said psychoactive compound is an antidepressant compound, an antipsychotic compound or an opioid compound.
5. A psychoactive compound reference expression profile, comprising a pattern of gene expression of two or more genes selected from the group consisting of PTX3, ILK, ENTPD6, GPCR CG50207, SFRS7, CBRC7TM_424 GPCR, APAF-1, ERMAP, CGFLC_31120, LYPLA1, LDHA, SCG3 and CG187132.
6. A method of identifying an agent that inhibits the expression or activity of a psychoactive-associated, comprising contacting a test cell expressing said psychoactive-associated gene with a test agent and determining the expression level of said psychoactive-associated gene, wherein a decrease of said level compared to a normal control level of said gene indicates that said test agent is an inhibitor of said psychoactive-associated gene.
7. A method of identifying an agent that enhances the expression or activity of a psychoactive-associated gene, comprising contacting a test cell expressing said psychoactive-associated gene with a test agent and determining the expression level or activity of the psychoactive-associated gene wherein an increase of said level or activity compared to a normal control

level or activity of said gene indicates that said test agent is an enhancer of the psychoactive-associated gene.

8. An array comprising a plurality of oligonucleotides which binds

a. the nucleic acid sequences of SEQ ID NO : 1-13 or

b. the nucleic acid sequences of at least four nucleic acid sequences selected from the group consisting of SEQ ID NO : 1-13.

9. A kit comprising a detection reagent that identifies :

a. the nucleic acid sequences of SEQ ID NO : 1-13 or

b. the nucleic acid sequences of at least four nucleic acid sequences selected from the group consisting of SEQ ID NO : 1-13.